IMO there is a distinct risk of Abeyratne’s work not reaching its potential because of the sell-out.
Once it’s commercial value had been established by Medgate and Alodokter there was every likelihood of other telehealth providers coming in to approach ResApp seeking similar contracts. They may be far more reluctant now in needing to deal with Pfizer, considering its reputation.
Only an issue that would be of concern to the long-term holders of course.
- Forums
- ASX - By Stock
- RAP
- Ann: Notification of cessation of securities - RAP
Ann: Notification of cessation of securities - RAP, page-22
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online